Antibodies 2013, 2(1), 82-92; https://doi.org/10.3390/antib2010082
An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells
1
Department of Pharmacology, University of Minnesota, 210 Delaware Street Southeast Minneapolis, MN 55455, USA
2
Department of Therapeutic Radiology-Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Masonic Cancer Center, 425 East River Parkway Minneapolis, MN 55455, USA
*
Author to whom correspondence should be addressed.
Received: 6 December 2012 / Revised: 19 January 2013 / Accepted: 22 January 2013 / Published: 28 January 2013
(This article belongs to the Special Issue Recombinant Immunotoxins)
View Full-Text
|
Download PDF [169 KB, uploaded 28 January 2013]
Abstract
Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use targeted therapies such as targeted toxins to bind and kill these cells selectively. A number of targeted toxins have been developed against recently identified cancer stem cell markers. In this review we discuss the development and current status of these exciting novel drugs and their potential use to combat drug-refractory relapse. View Full-TextKeywords:
cancer stem cells; targeted toxins; immunotoxins; CD133; EpCAM; CD123; CD44
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Waldron, N.N.; Vallera, D.A. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies 2013, 2, 82-92.
Related Articles
Article Metrics
Comments
[Return to top]
Antibodies
EISSN 2073-4468
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert